However, whether and how PIKfyve serves as a target for upregulating tumor-specific MHC-I surface expression and whether apilimod or ESK981 treatment augments CD8+ T cell–dependent immunotherapies remain to be explored. The gene discussed is CD8A; the disease is neoplasm.